110958-19-5|Fasoracetam|(R)-1-((5-Oxo-2-pyrrolidinyl)carbonyl)piperidine|-范德生物科技公司

Fasoracetam

NMR下载 COA and HPLC MSDS下载
names：
(R)-1-((5-Oxo-2-pyrrolidinyl)carbonyl)piperidine
CAS号：
110958-19-5
MDL Number：
MF(分子式)： C10H16N2O2 MW(分子量)： 196.25
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Fasoracetam
英文别名	Fasoracetam; N-(5-Oxo-D-prolyl)piperidine; NS-105; NFC-1; LAM-105.
CAS号	110958-19-5
SMILES	O=C(N1CCCCC1)[C@@H](CC2)NC2=O
Inchi	InChI=1S/C10H16N2O2/c13-9-5-4-8(11-9)10(14)12-6-2-1-3-7-12/h8H,1-7H2,(H,11,13)/t8-/m1/s1
InchiKey	GOWRRBABHQUJMX-MRVPVSSYSA-N
分子式 Formula	C10H16N2O2
分子量 Molecular Weight	196.25
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Fasoracetam(CAS:110958-19-5):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Fasoracetam, also known as NS-105; NFC-1; LAM-105, is a GABA receptor modulator potentially for the treatment of attention deficit hyperactivity disorder. It is a nootropic, and has been in a clinical trial for attention deficit hyperactivity disorder. In in vitro studies on mouse neurons, fasoracetam modulated mGluR II/III activity. In studies in rats, it blocked memory disruptions caused by baclofen, a GABAB agonist and upregulated production of GABAB receptors after repeat dosing.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Chugh G, Asghar M, Patki G, Bohat R, Jafri F, Allam F, Dao AT, Mowrey C, Alkadhi K, Salim S. A high-salt diet further impairs age-associated declines in cognitive, behavioral, and cardiovascular functions in male Fischer brown Norway rats. J Nutr. 2013 Sep;143(9):1406-13. doi: 10.3945/jn.113.177980. Epub 2013 Jul 17. PubMed PMID: 23864508; PubMed Central PMCID: PMC3743272.

[2]Fasoracetam. LAM 105, NS 105. Drugs R D. 1999 Aug;2(2):135-6. PubMed PMID: 10820660.

[3] Mukai H, Sugimoto T, Ago M, Morino A, Takaichi M, Ogawa Y, Seki H, Matsuura C, Esumi Y. Pharmacokinetics of NS-105, a novel cognition enhancer. 2nd communication: distribution and transfer into fetus and milk after single administration, and effects of repeated administration on pharmacokinetics and hepatic drug-metabolizing enzyme activities in rats. Arzneimittelforschung. 1999 Dec;49(12):977-85. PubMed PMID: 10635441.

[4] Hirouchi M, Oka M, Itoh Y, Ukai Y, Kimura K. Role of metabotropic glutamate receptor subclasses in modulation of adenylyl cyclase activity by a nootropic NS-105. Eur J Pharmacol. 2000 Jan 3;387(1):9-17. PubMed PMID: 10633154.

[5] Mukai H, Sugimoto T, Ago M, Morino A. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105. Arzneimittelforschung. 1999 Nov;49(11):881-90. PubMed PMID: 10604039.

6: Ogasawara T, Itoh Y, Tamura M, Mushiroi T, Ukai Y, Kise M, Kimura K. Involvement of cholinergic and GABAergic systems in the reversal of memory disruption by NS-105, a cognition enhancer. Pharmacol Biochem Behav. 1999 Sep;64(1):41-52. PubMed PMID: 10494996.7: Kumagai Y, Yokota S, Isawa S, Murasaki M, Mukai H, Miyatake S. Comparison of pharmacokinetics of NS-105, a novel agent for cerebrovascular disease, in elderly and young subjects. Int J Clin Pharmacol Res. 1999;19(1):1-8. PubMed PMID: 10450537.8: Shimidzu T, Itoh Y, Oka M, Ishima T, Ukai Y, Yoshikuni Y, Kimura K. Effect of a novel cognition enhancer NS-105 on learned helplessness in rats: possible involvement of GABA(B) receptor up-regulation after repeated treatment. Eur J Pharmacol. 1997 Nov 12;338(3):225-32. PubMed PMID: 9424016.9: Oka M, Itoh Y, Tatsumi S, Ma FH, Ukai Y, Yoshikuni Y, Kimura K. A novel cognition enhancer NS-105 modulates adenylate cyclase activity through metabotropic glutamate receptors in primary neuronal culture. Naunyn Schmiedebergs Arch Pharmacol. 1997 Aug;356(2):189-96. PubMed PMID: 9272724.10: Oka M, Itoh Y, Shimidzu T, Ukai Y, Yoshikuni Y, Kimura K. Involvement of metabotropic glutamate receptors in Gi- and Gs-dependent modulation of adenylate cyclase activity induced by a novel cognition enhancer NS-105 in rat brain. Brain Res. 1997 Apr 18;754(1-2):121-30. PubMed PMID: 9134967.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开